Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 14
Submit an article Journal homepage
269
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

Karthik Natha Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-3881-5681View further author information
ORCID Icon,
Tala Shekarkhandb Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Meghan Salcedob Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Andriy Derkachc Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Siobhan Ruedad Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USAView further author information
,
Aisara Chansakule Emergency Department, Division of Emergency Medicine, Weill Cornell Medical College, New York, NY, USAView further author information
,
Malin Hulcrantzb Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Neha Kordeb Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-5538-4318View further author information
ORCID Icon,
Urvi A. Shahb Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-8419-1091View further author information
ORCID Icon,
Carlyn Tanb Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-7922-2594View further author information
ORCID Icon,
David J. Chunga Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;f Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-0469-839XView further author information
ORCID Icon,
Oscar B. Lahoudf Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-3291-286XView further author information
ORCID Icon,
Hani Hassounb Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-2036-1749View further author information
ORCID Icon,
Alexander M. Lesokhina Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-9321-702XView further author information
ORCID Icon,
Heather J. Landauf Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-3152-1189View further author information
ORCID Icon,
Gunjan Shaha Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;f Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Michael Scordoa Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;f Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Sergio A. Giralta Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;f Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-1944-5053View further author information
ORCID Icon,
Saad Z. Usmania Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Mikhail Roshalg Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Ola Landgrenh Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USAORCID Iconhttps://orcid.org/0000-0001-6485-4839View further author information
ORCID Icon &
Sham Mailankodya Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2815-9561View further author information
ORCID Icon show all
Pages 3488-3492 | Received 09 Jun 2022, Accepted 20 Sep 2022, Published online: 25 Oct 2022

References

  • Anderson KC, Auclair D, Kelloff GJ, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin Cancer Res. 2017;23(15):3980–3993.
  • Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
  • Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35(25):2900–2910.
  • Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large Meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–5999.
  • Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–2464.
  • Landgren O, Devlin S, Boulad M, et al. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant. 2016;51(12):1565–1568.
  • Mohan M, Kendrick S, Szabo A, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022;6(3):808–817.
  • Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
  • Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945.
  • Roshal M, Flores-Montero JA, Gao Q, et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Advances. 2017;1(12):728–732.
  • Landgren O, Hultcrantz M, Diamond B, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 2021;7(6):862–868.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.